CARLSBAD, Calif., June 2 Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at two investor conferences in the month of June, 2010.
Advertisement
EVP & CFO Doug Schuling will present at the Bank of America Merrill Lynch SMID Cap Conference at the InterContinental Hotel in Boston, Mass. beginning at 8:50 a.m. EDT on Tuesday, June 8, 2010.
Advertisement
President and CEO Tina S. Nova, Ph.D., and Sam Riccitelli, EVP and COO, will present at the William Blair & Company's 30th Annual Growth Stock Conference at the Four Seasons Hotel, Chicago, Ill. on Wednesday, June 16, 2010 beginning at 11:20 a.m. EDT.
Each presentation will be web cast live through the "Investors" section of the Genoptix website at www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. An audio replay will be available for 30 days following the initial presentation web cast.
About Genoptix, Inc.
Genoptix is a leading specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to its physician customers, community-based hematologists and oncologists. On the forefront of personalized diagnostic services, Genoptix's highly trained group of hematopathologists utilize sophisticated technology to provide integrated testing and actionable diagnostic reports. Its diagnostic services are designed to optimize the care of patients suffering from hematomalignancies, or cancers of the blood and bone marrow, including leukemia and lymphoma, and other forms of cancer. Founded in 1999, Genoptix is a member of the Nasdaq Global Select Market, the S&P SmallCap 600 Index and the Russell 2000 Index and is headquartered in Carlsbad, California. For more information, please visit www.genoptix.com.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.
SOURCE Genoptix, Inc.
